ObsEva SA (OBSV) News
Filter OBSV News Items
OBSV News Results
|Loading, please wait...|
OBSV News Highlights
- OBSV's 30 day story count now stands at 15.
- Over the past 16 days, OBSV's stories per day has been in a clear uptrend, growing by about 2.00 per 8 days.
- The most mentioned tickers in articles about OBSV are SA, AGE and ABT.
Latest OBSV News From Around the Web
Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.
(RTTNews) - ObsEva SA (OBSV) said Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options.
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -
ObsEva SA: ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive dat
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P
ObsEva SA (NASDAQ: OBSV) has submitted a marketing application to the FDA seeking approval for linzagolix for uterine fibroids. Linzagolix is an oral GnRH receptor antagonist. Related Link: ObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study. The Company believes that if approved, linzagolix will be the only GnRH antagonist in uterine fibroids with a low dose non-add-back therapy (ABT) option. The submission includes 52-week treatment results from the Phase 3 PRIMROSE 1 (th
GENEVA, Switzerland September 7 , 202 1 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23 rd Annual Global Investment Conference to be held September 13-15, 2021.
GENEVA, Switzerland September 7, 2021 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women''s reproductive health, today
Heavy Menstrual Bleeding (HMB) Market Amazing Demand 3X Revenues by 2021-2028 with ObsEva, AbbVie, Myovant Sciences, Bayer, Enteris BioPharma, Ferring Pharmaceuticals
Heavy menstrual bleeding (HMB) is one of the most common gynecological disorders affecting women of reproductive age. It is subjectively defined as heavy cyclical menstrual bleeding occurring over several consecutive cycles. As observed, it is a total blood loss of
Penny stocks from companies that have reasonable business fundamentals.